Proteomics for Chronic Kidney Disease Therapy

Informations projet

PROCEED

N° de convention de subvention: 799993

DOI

10.3030/799993

Projet clôturé le 31 Août 2019

Date de signature de la CE 5 Juillet 2018

Date de début 1 Août 2018

Date de fin 28 Février 2021

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total

€ 171 460,80

Contribution de l’UE

€ 171 460,80

Coordonné par

MOSAIQUES DIAGNOSTICS GMBH
Germany

Periodic Reporting for period 1 - PROCEED (Proteomics for Chronic Kidney Disease Therapy)

Période du rapport: 2018-08-01 au 2020-07-31

Résumé du contexte et des objectifs généraux du projet

The social and financial burden that chronic kidney disease (CKD) imposes on European countries is significant. Currently 16.95% of the global population suffers from CKD. The prevalence of the disease has increased steadily during the previous decades and it is expected to reach alarming rates in the near future. It is thus apparent that an effective treatment for CKD will have a positive social and financial impact. The pathological basis of CKD is complex and the molecular mechanisms responsible for the onset and progression of the disease have not been fully elucidated. Their elucidation will enable the identification of specific therapeutic targets. Currently there are significant molecular datasets available on CKD deposited in databases. However, a marked deficiency of these datasets is the scarcity of kidney tissue proteomics data. PROCEED targets the mapping of kidney tissue proteomics changes in association to CKD phenotypes, integration of molecular datasets with clinical data by systems biology approaches, and subsequently prediction of novel therapeutic targets. In order to obtain a detailed molecular profile of the kidney the two main morphological features, glomeruli and tubules will be isolated and their proteins will be identified. The output of the proposed study is expected to fill a very important gap in the existing knowledge in the field, namely provide the in situ comprehensive proteomics phenotyping of renal disease progression. The project is timely and in accordance with the current European research developments and societal needs.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Initially mouse kidneys were collected and thin sections were placed on microscope slides. Then, a protocol was established based on laser capture microdissection for isolation of tubules and glomeruli. Mass spectrometry based analysis was performed in order to identify the protein components of these anatomical regions of the kidney.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The identified proteins are a valuable dataset that will be examined in detail in the future. Analysis of human samples from controls and CKD patients is pending and will result in the identification of putative therapeutic targets.

proceed-picture.jpg